熱門資訊> 正文
另外，FDA批准开始ReyobiqTM试验后，Thereutics上涨
2025-06-25 21:45
- Shares of Plus Therapeutics (NASDAQ:PSTV) more than doubled after the U.S. FDA cleared the trial initiation for its injectable radiotherapy, Reyobiqtm, to treat pediatric patients with progressive high-grade glioma and ependymoma.
- The trial, known as the ReSPECT-PBC trial, is funded by a $3M research grant from the United States Department of Defense.
- The shares are up 114%.
More on Plus Therapeutics
- Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript
- Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering
- Plus Therapeutics receives Nasdaq delinquency notice
- Seeking Alpha’s Quant Rating on Plus Therapeutics
- Historical earnings data for Plus Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
